Bliss GVS Pharma

Catalyst Trusteeship disclosed creation of a pledge over 5,09,84,595 equity shares of Bliss GVS Pharma, representing 47.95% of voting capital and 46.77% on a diluted basis, on 30 September 2026 as debenture trustee for debenture holders. The disclosure came two days after Anupam Rasayan and Mates Visa consummated acquisition of control on 28 September with a 50.07% holding and reconstituted the board with three additional directors. Bliss GVS reported consolidated revenue of ₹927 crore in FY26, up 14% year on year, with exports accounting for about 91% of sales and Sub-Saharan Africa about 80%. The company held net cash of ₹258 crore at the end of FY26 with borrowings down 96%, while consolidated revenue reached ₹285.6 crore in the June quarter with net profit of ₹51.4 crore.

Powered by Tijori

Bliss GVS Pharma's board approved two employee stock option schemes on 1 October 2026 at a meeting held through video conferencing. The Senior Executive ESOP 2026 covered up to 26.5 lakh shares representing about 2.49% of paid-up capital and the Employee ESOP 2026 covered up to 47 lakh shares representing about 4.42%, both at an exercise price of Rs10 per share. The board also approved grants of stock options equal to or exceeding 1% of issued capital to identified employees in any one year, with both schemes subject to shareholder approval. Control of the company changed on 28 September 2026 when Anupam Rasayan and Mates Visa Consultancy acquired 5,32,36,264 shares representing 50.07% of equity. Consolidated revenue was Rs927 crore in the year to March 2026 with net profit of Rs134.7 crore, while revenue for the June quarter was Rs285.6 crore with net profit of Rs51.4 crore. The company commissioned its Vevoor semi-solids plant during the year to March, adding about 200 million units, and derived about 30% of sales from Greenlife with exports at about 91% of revenue.

Powered by Tijori

Bliss GVS Pharma's board noted the completion of the share purchase agreement dated 23 May 2026 under which Anupam Rasayan India and its assignee Mates Visa Consultancy acquired control after the transfer of promoter shares and the completion of the open offer. The board reclassified 27 outgoing promoter and promoter group members to the public category with effect from 28 September 2026. Their combined holding fell from 3,71,30,124 shares representing 34.82% to 8,100 shares representing 0.01%, with Narsimha Shibroor Kamath's 30.51% moving to nil. The promoter group had agreed in May to sell a 31.59% stake at Rs299 per share, and a draft offer for a further 26% at the same price was filed in June. The company's independent directors described the Rs299 offer price as fair and reasonable in July, when the market price stood around Rs482-483.50. Bliss GVS Pharma derived about 91% of revenue from outside India and reported consolidated revenue of about Rs927 crore in FY26. It held net cash of Rs258 crore at the end of FY26, with its Vevoor semi-solids plant adding about 200 million units of capacity.

Powered by Tijori

Bliss GVS Pharma transferred control on 28 September 2026 as Mates Visa Consultancy acquired 5,09,84,595 equity shares, representing 47.95% of equity capital, under the 23 May share purchase agreement with Anupam Rasayan India, taking the combined Anupam-Mates holding to 5,09,86,264 shares including 1,669 shares bought in the open offer. Anupam Rasayan and Mates Visa acquired control and became promoters with effect from that date. The board appointed Hetul Krishnakant Mehta, Amar Dilip Shah and Pramod Badrinarayan Kasat as additional non-executive non-independent directors, noted the resignation of managing director Narsimha Shibroor Kamath, and approved a postal ballot for shareholder approval of the three appointments. The completion followed the May agreement for promoters to sell 31.59% at ₹299 per share and the June draft offer for 26% at the same price, which an independent committee described as fair in July when the shares traded around ₹482. ChrysCapital's Clarus Trust crossed 5.13% in July while LIC reduced its holding from 5.11% to 2.96% through August. The company reported consolidated revenue of about ₹927 crore for FY26 and ₹285.6 crore for the June quarter, held net cash of ₹258 crore with borrowings down 96%, and derived about 30% of FY26 sales from Greenlife.

Powered by Tijori

Bliss GVS Pharma completed the transfer of a 47.95% equity stake to Mates Visa Consultancy Private Limited and Anupam Rasayan India Limited on 28 September 2026. The purchasers acquired 5,09,86,264 shares, including 1,669 shares tendered in the open offer, and became the company's promoters with control. The board appointed Hetul Krishnakant Mehta, Amar Dilip Shah and Pramod Badrinarayan Kasat as additional non-executive non-independent directors and noted the resignation of managing director Narsimha Shibroor Kamath, with a postal ballot to seek shareholder approval for the appointments. The closing followed a 23 May share purchase agreement under which the promoter group agreed to sell a 31.59% stake at Rs299 per share and a draft open offer for 26% at the same price filed in June. An independent directors committee described the Rs299 offer price as fair and reasonable in July, when the market price stood around Rs482 to Rs483.50. Bliss GVS reported consolidated revenue of about Rs927 crore in FY26 with exports at 91% of sales and revenue of Rs285.6 crore in the June quarter.

Powered by Tijori

Bliss GVS Pharma’s board approved the appointment of Rahul Adakmol as chief executive officer, effective 15 July 2026, the company said on Thursday. He replaces Narsimha Shibroor Kamath, who will step down as CEO at the close of business on 14 July but continue as managing director. Adakmol, a chemical engineer and IIM Bangalore alumnus, brings over 22 years of experience from leadership roles at Dr. Reddy’s Laboratories, Bharat Serums and Vaccines, and Reliance Industries. In a resignation letter, Kamath said the transition was the right time for new energy to lead the company’s next growth phase, and he would ensure a smooth handover. The board also appointed Santosh Parab, a former independent director, as an additional non-executive non-independent director.

Powered by Tijori

July 3 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA - APPOINTS RAHUL ADAKMOL AS CEO EFFECTIVE JULY 15, 2026

• BLISS GVS PHARMA - NARSIMHA SHIBROOR KAMATH RESIGNS AS CEO EFFECTIVE JULY 14, 2026

Source text: ID:nBSE2FsYwW

Further company coverage: BLIS.NS

(([email protected];))

June 2 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - RECEIVED AN INSPECTION CLOSURE REPORT FROM WORLD HEALTH ORGANIZATION

• BLISS GVS PHARMA - PALGHAR FACILITY HAS BEEN CONFIRMED TO BE IN COMPLIANCE WITH GOOD MANUFACTURING PRACTICES

Source text: ID:nBSE5nDDM8

Further company coverage: BLIS.NS

(([email protected];))

** Bliss GVS Pharma BLIS.NS stock rises more than 2% to 307.35 rupees, Anupam Rasayan India ANUY.NS down 1.5%

** Specialty chem firm ANUY to buy up to 74.2% Bliss stake, according to filing

** 45.8 mln shares, equivalent to 43.3% stake, for up to 13.7 bln rupees ($143.7 mln) from promoters and investors, 26% stake from public shareholders worth 8.29 bln rupees

** ANUY also has an option to acquire another 4.9% residual stake from sellers

** YTD, BLIS up about 88% and ANUY up around 2%

($1 = 95.3675 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

Feb 10 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• DEC-QUARTER CONSOL NET PROFIT 232.7 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 2.18 BILLION RUPEES

Source text: ID:nBSEc1pHyZ

Further company coverage: BLIS.NS

(([email protected];))

Nov 6 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD SEPT-QUARTER CONSOL NET PROFIT 272.5 MILLION RUPEES

• BLISS GVS PHARMA LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.44 BILLION RUPEES

Source text: ID:nBSE7g0K3j

Further company coverage: BLIS.NS

(([email protected];;))

Oct 7 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - RECEIVES TAX DEMAND OF 166.9 MILLION RUPEES FROM TAX DEPARTMENT

Source text: ID:nNSE7qpMNB

Further company coverage: BLIS.NS

(([email protected];))

Sept 30 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - APPOINTS NARSIMHA SHIBROOR KAMATH AS CEO

Source text: ID:nBSE7sZhBb

Further company coverage: BLIS.NS

([email protected])

July 29 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 430.4 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.07 BILLION RUPEES

Source text: [ID:]

Further company coverage: BLIS.NS

(([email protected];;))

July 2 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA LTD - GETS SHOW CAUSE FROM TAX DEPARTMENT OVER RECOVERY OF REFUND OF 66.4 MILLION RUPEES

Source text: ID:nBSE46BZkl

Further company coverage: BLIS.NS

(([email protected];;))

April 15 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• RISING PHARMA HOLDINGS GETS FINAL APPROVAL FROM USFDA FOR MESALAMINE SUPPOSITORIES

Source text: [ID:]

Further company coverage: BLIS.NS

(([email protected];;))

Jan 21 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• TO CONSIDER ISSUANCE OF SWEAT EQUITY SHARES

Source text: ID:nBSE7zTS7Z

Further company coverage: BLIS.NS

(([email protected];;))

July 24 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 207 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.84 BILLION RUPEES

Source text for Eikon: ID:nBSE2Py5qt

Further company coverage: BLIS.NS

(([email protected];))

Feb 16 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• APPROVED AN INTERNAL RESTRUCTURING OF FOREIGN SUBSIDIARIES OF COMPANY

Source text for Eikon: ID:nBSE2BQhKM

Further company coverage: BLIS.NS

(([email protected];;))

Sept 7 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• ASSISTANT COMMISSION OF STATE TAX MAHARASHTRA INITIATED SEARCH ON SEPT 6 AT CERTAIN PREMISES OF CO

• NO IMPACT ON OPERATIONS, OR ANY OTHER ACTIVITIES OF CO EXPECTED AS OF NOW

Source text for Eikon: ID:nBSEqz51y

Further company coverage: BLIS.NS

(([email protected];;))

** Shares of Indian drugmaker Bliss GVS Pharma BLIS.NS fall as much as 6.87% to 91.55 rupees in sharpest intraday slide since May 12

** Co posted more than 43% slide in consol net profit at 146.9 mln rupees ($1.78 million) for the quarter ended June 30, while rev slipped more than 11% to 1.60 bln rupees

** Stock on track for fourth consecutive session of losses

** More than 400,00 shares changed hands by 10:09 a.m. IST, 0.8X 30-day avg

** BLIS has risen 28% so far this year

($1 = 82.4425 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Aug 1 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• INDIA'S BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 146.9 MILLION RUPEES VERSUS PROFIT 257.2 MILLION RUPEES

• BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.6 BILLION RUPEES VERSUS 1.89 BILLION RUPEES

Source text for Eikon: ID:nBSEjtHVV

Further company coverage: BLIS.NS

(([email protected];;))

June 15 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS:

• GOT ESTABLISHMENT INSPECTION REPORT FOR PALGHAR UNIT FROM US FDA

• US FDA AGENCY ASSIGNED INSPECTION CLASSIFICATION OF FACILITY AS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE24NSlj

Further company coverage: BLIS.NS

(([email protected];;))